SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
AMENDMENT NO. 3
TO
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO
FILED PURSUANT TO RULE 13d-2(a)
NUR MACROPRINTERS LTD.
--------------------------------------------------------------------------------
(Name of Issuer)
ORDINARY SHARES,
NIS 1.0 NOMINAL VALUE
--------------------------------------------------------------------------------
(Title of Class of Securities)
M75165106
--------------------------------------------------------------------------------
(CUSIP Number)
Dan Purjes, 200 Park Avenue, 25th Fl., New York, NY, 10166
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
October 23, 2000
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g)
check the following box / /.
Note. Schedule filed in paper format shall include a signed original and
five copies of this schedule, including all exhibits. See Rule 13d-7 for
other parties to whom copies are to be sent.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
<PAGE>
CUSIP NO. M75165106 13D Page 1 of 7
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Dan Purjes
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / /
(b) / /
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
PF
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e) / /
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 4,112,099
SHARES
BENEFICIALLY ----------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING 555,024
PERSON
WITH ----------------------------------------
9 SOLE DISPOSITIVE POWER
4,112,099
----------------------------------------
10 SHARED DISPOSITIVE POWER
555,024
<PAGE>
CUSIP NO. M75165106 13D Page 2 of 7
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,667,123
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
32.4%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT.
Item 1. Security and Issuer.
The securities are Ordinary Shares of NUR MACROPRINTERS LTD. ("NUR"). NUR's
principal executive offices are located at 5 David Navon Street, Moshav
Magashimim, 56910 Israel.
Item 2. Identity and Background.
(a) The name of the person filing this Schedule is Dan Purjes.
(b) The business address of Dan Purjes, c/o Josephthal Group, Inc., 200 Park
Avenue, 25th Fl., New York, NY, 10166.
(c) Mr. Purjes is the Chairman of the Board, Chief Executive Officer and
indirect controlling shareholder of Josephthal Group, Inc. and indirect
controlling shareholder of Josephthal & Co. Inc. ("Josephthal"), a
subsidiary of Josephthal Group, Inc. and a broker-dealer duly licensed
under Section 15 of the Securities Exchange Act of 1934, as amended.
(d) No criminal convictions in the last five years (excluding traffic
violations or similar misdemeanors).
(e) No judgment, decrees, or final orders with regard to violations of
securities laws in the last five years.
(f) United States citizen.
<PAGE>
CUSIP NO. M75165106 13D Page 3 of 7
Item 3. Source and Amount of Funds or Other Consideration.
The table below details the Ordinary Shares of NUR beneficially owned by
Dan Purjes:
# of Shares Amount of Funds Nature of Ownership
17,000 $40,162.50 Direct / Dan Purjes
100,000 $233,250.00 Direct / Dan Purjes
5,000 $11,875.00 Indirect / UGMA Lianna Purjes1
100,000 $156,250.00 Direct / Dan Purjes
1,000 $2,750.00 Direct / Dan Purjes
5,000 $11,078.75 Direct / Dan Purjes2
25,000 $25,000.00 Direct / Dan Purjes Joint
Tenant with Mary Vitullo
190,000 $190,000.00 Direct / Dan Purjes3
223,780 $201,402.00 Direct / Dan Purjes3
2,500,000 $2,660,000.00 Direct / Dan Purjes3,4
12,500 $12,500.00 Direct / Dan Purjes Joint
Tenant with Adrian Beck
174,200 $129,965.00 Indirect / J. Partners, L.P.5
35,664 $142,656.00 Indirect / Josephthal & Co. Inc.6
7,000 $17,864.50 Indirect / J. Partners, L.P.7
5,000 $10,000.00 Direct / Dan Purjes3
44,000 $126,830.00 Indirect / J. Partners, L.P.
100,000 $275,750.00 Indirect / J. Partners, L.P.
25,000 $67,457.50 Direct / Dan Purjes
71,000 $201,107.50 Direct / Dan Purjes
10,000 $27,084.60 Indirect /UGMA Lianna Purjes1
2,000 $5,643.60 Indirect / Sugarhouse Follies
50,000 $134,875.00 Direct / Dan Purjes2
1,000 $5,330.00 Indirect / J. Partners, L.P.
5,000 $25,850.00 Indirect / J. Partners, L.P.
5,000 $26,650.00 Indirect / J. Partners, L.P.
2,000 $10,890.00 Indirect / J. Partners, L.P.
2,000 $10,535.00 Indirect / J. Partners, L.P.
3,000 $15,990.00 Indirect / J. Partners, L.P.
14,000 $73,229.80 Indirect / J. Partners, L.P.
1,000 $5,445.00 Indirect / J. Partners, L.P.
28,800 $160,416.00 Indirect / J. Partners, L.P.
30,600 $192,911.58 Indirect / J. Partners, L.P.
14,000 $93,917.40 Indirect / J. Partners, L.P.
4,000 $24,163.50 Indirect / J. Partners, L.P.
8,100 $49,617.36 Indirect / J. Partners, L.P.
500 $2,915.00 Indirect / J. Partners, L.P.
5,000 $29,150.00 Indirect / J. Partners, L.P.
<PAGE>
CUSIP NO. M75165106 13D Page 4 of 7
2,000 $11,160.00 Indirect / J. Partners, L.P.
6,000 $39,994.80 Direct / Dan Purjes
10,000 $105,000.00 Indirect / J. Partners, L.P.
15,000 $179,793.75 Indirect / J. Partners, L.P.
5,000 $58,175.00 Direct / Dan Purjes
5,000 $78,525.00 Indirect / J. Partners, L.P.
5,000 $67,018.83 Direct / Dan Purjes
1,000 $14,580.00 Indirect / J. Partners, L.P.
3,000 $41,290.00 Direct / Dan Purjes
5,000 $67,275.00 Indirect / J. Partners, L.P.
2,000 $24,549.60 Indirect / Sugarhouse Follies
7,000 $86,168.35 Indirect / J. Partners, L.P.
3,000 $50,290.00 Direct / Dan Purjes
3,000 $49,614.90 Indirect / J. Partners, L.P.
2,000 $28,910.00 Indirect / J. Partners, L.P.
2,000 $29,160.00 Indirect / J. Partners, L.P.
1,000 $14,528.95 Direct/Dan Purjes2
10,700 $161,837.50 Indirect / J. Partners, L.P.
60 $963.95 Indirect / Edna Purjes &
Pablita Wright JTWROS
1,000 $14,392.50 Indirect / J. Partners, L.P.
2,000 $28,660.00 Indirect / J. Partners, L.P.
3,000 $40,740.00 Indirect / J. Partners, L.P.
250,000 $312,500.00 Direct/ Dan Purjes8
10,000 $27,500.00 Direct/ Dan Purjes9
320,000 $320,000.00 Direct10
3,000 $38,145.00 Indirect / J. Partners, L.P.
4,100 $49,175.40 Indirect / J. Partners, L.P.
28,000 $291,911.20 Direct/Dan Purjes2
50,000 $525,000.00 Direct/Dan Purjes11
84,119 N/A Direct12
-------------------
1 There are 30,000 Ordinary Shares in the aggregate, of NUR held by Dan Purjes's
minor children. Dan Purjes does not have beneficial ownership of the 15,000
Ordinary Shares held by his former spouse as custodian for Mr. Purjes's son in a
uniform gift to minors act account.
2 These Ordinary Shares are held by Dan Purjes in his profit sharing plan.
3 These Ordinary Shares were originally purchased in the name of Dan Purjes and
on March 12, 1999 were transferred to WBMI, L.L.C., a Delaware limited liability
Company of which Dan Purjes owns all of the interests. On June 13, 2000, all
these Ordinary Shares were transferred to Dan Purjes.
4 Includes 2,500,000 Ordinary Shares that were acquired by WBM, L.L.C. ("WBM")
and Dan Purjes pursuant to a default on a $2,500,000 personal loan made to Moshe
Nuri, one of the founders of NUR. WBM is a Delaware limited liability company of
which Dan Purjes owns a controlling interest and is the managing member. Also
includes 80,000 Ordinary Shares that Mr. Purjes purchased from WBM in a private
transaction in January 1999. On June 13, 2000, all these Ordinary Shares were
transferred to Dan Purjes.
5 Includes 88,000 Ordinary Shares originally purchased and held in the name of
Dan Purjes and subsequently deposited into J. Partners, L.P. Also includes
86,200 Ordinary Shares deposited into J. Partners, L.P. by clients of Dan Purjes
and Josephthal. J. Partners, L.P. is a Delaware partnership of which Dan Purjes
owns 100% of the equity of the general partner and is also a limited partner.
6 These 35,664 Ordinary Shares are held by Josephthal, of which Dan Purjes is
indirect controlling shareholder.
7 J. Partners, L.P. is a Delaware limited partnership of which Dan Purjes owns
100% of the equity of the general partner, J. Partners, Inc.
8 Represents 250,000 Ordinary Shares issued to Dan Purjes upon his exercise of
250,000 five year stock options, at an exercise price of $1.25 per Ordinary
Share, issued to Dan Purjes for services as a director in November 1997.
<PAGE>
CUSIP NO. M75165106 13D Page 5 of 7
9 Represents 10,000 Ordinary Shares issued to Dan Purjes upon his exercise of
10,000 five year stock options, at an exercise price of $2.75 per Ordinary
Share, issued to Dan Purjes for services as a director in October 1998.
10 Represents 320,000 Ordinary Shares issued to Dan Purjes upon his exercise of
320,000 five year warrants, at an exercise price of $1.00 per Ordinary Share,
issued in December 1997, as compensation for services in connection with a
private placement of the Company's securities. 5,000 of such warrants were
originally issued to another individual and were subsequently purchased by Dan
Purjes in a private transaction. 10,000 of such warrants were originally issued
to another entity and subsequently purchased by Dan Purjes in a private
transaction.
11 Represents 50,000 Ordinary Shares acquired by Dan Purjes pursuant to a Stock
Transfer Agreement dated as of October 25, 2000 in connection with a debt
settlement of Esther Purjes.
12 Represents 84,119 Ordinary Shares issuable upon exercise of 84,119 five year
warrants, at an exercise price of $7.20 per Ordinary Share, issued in October
1995, as compensation for services in connection with the Company's initial
public offering.
Item 4. Purpose of Transaction.
Dan Purjes entered into a Shareholders Agreement dated as of August 18,
1999 which became effective on September 1, 1999 (the "Shareholders Agreement")
with Isal Amlat Investment Ltd. ("Isal"), whereby concurrently with the
execution of the Shareholders Agreement, Isal, together with Dovrat & Co. Ltd.
("Dovrat") was to execute a Share and Warrant Purchase Agreement with NUR
Macroprinters Ltd. ("NUR") whereby Isal and Dovrat purchased an aggregate of
600,000 Ordinary Shares of NUR and Warrants exercisable into an aggregate of
150,000 Ordinary Shares. Pursuant to the Shareholders Agreement, Dan Purjes
agreed to exercise the voting power of the NUR Ordinary Shares held or
controlled by him with respect to the appointment of one member, to be
designated by Isal, to the Board of Directors of NUR and to grant Isal certain
co-sale rights upon the sale of Ordinary Shares held by Dan Purjes. The
Shareholders Agreement shall terminate at such time when (i) Isal shall hold
Ordinary Shares representing less than 4% of NUR's issued share capital, and/or
(ii) the aggregate number of Ordinary Shares held or controlled by Dan Purjes
(not including any warrants or options held by Dan Purjes) shall be equal to or
less than 20% of NUR's issued share capital. For purposes of the Shareholders
Agreement, in determining the number of Ordinary Shares owned, warrants shall be
considered exercised.
Item 5. Interest in Securities of the Issuer.
(a) The aggregate of 4,667,123 Ordinary Shares of NUR are beneficially held by
Mr. Purjes, constituting 32.4% of the outstanding Ordinary Shares of NUR
based upon 14,314,395 Ordinary Shares outstanding as of October 12, 2000,
as set forth in the Company's Report on Form 6-K dated October 23, 2000,
Commission File No. 0-26498.
(b) Mr. Purjes owns 4,112,099 Ordinary Shares of NUR which he holds the sole
power to vote and the sole power to dispose of or direct the disposition.
Mr. Purjes owns 555,024 Ordinary Shares of NUR with respect to which he
holds the shared power to vote and the shared power to dispose of or to
direct the disposition.
(c) There were four transactions since the filing of Amendment No. 2 to
Schedule 13D as follows:
J. Partners, L.P. purchased 3,000 Ordinary Shares for an aggregate purchase
price of $38,145.00 in the open market on October 5, 2000.
<PAGE>
CUSIP NO. M75165106 13D Page 6 of 7
J. Partners, L.P. purchased 4,100 Ordinary Shares for an aggregate purchase
price of $49,175.40 in the open market on October 6, 2000.
Dan Purjes Profit Sharing Plan purchased 28,000 Ordinary Shares for an
aggregate purchase price of $291,911.20 in the open market on October 9,
2000.
Dan Purjes acquired 50,000 Ordinary Shares pursuant to a Stock Transfer
Agreement dated as of October 25, 2000 for an aggregate purchase price of
$525,000.00 in connection with a debt settlement of Esther Purjes.
(d) Not applicable.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationship With respect
to Securities of the Issuer.
None.
Item 7. Materials to be Filed as Exhibits.
None.
<PAGE>
CUSIP NO. M75165106 13D Page 7 of 7
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, correct and complete.
DATED: October 27, 2000
/s/ Dan Purjes
------------------------------
Dan Purjes
